Q3 EPS Forecast for Xenon Pharmaceuticals Raised by Analyst

Key Points

• Leerink Partners has increased its Q3 2025 earnings estimate for Xenon Pharmaceuticals from ($1.16) to ($1.14) per share.
• Xenon Pharmaceuticals reported a Q2 earnings loss of ($1.07) per share, missing analyst expectations of ($1.03) by $0.04.
• Despite mixed ratings from various analysts, the average consensus rating for Xenon Pharmaceuticals is "Moderate Buy" with a target price of $53.20.

Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) - Equities researchers at Leerink Partnrs raised their Q3 2025 earnings per share estimates for Xenon Pharmaceuticals in a research note issued on Monday, August 11th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of ($1.14) for the quarter, up from their previous estimate of ($1.16). The consensus estimate for Xenon Pharmaceuticals' current full-year earnings is ($3.10) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals' Q4 2025 earnings at ($1.21) EPS, FY2025 earnings at ($4.25) EPS, FY2026 earnings at ($4.80) EPS, FY2027 earnings at ($4.30) EPS and FY2028 earnings at ($3.00) EPS.

Other research analysts have also issued reports about the company. HC Wainwright restated a "buy" rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research report on Tuesday, May 13th. Needham & Company LLC decreased their target price on Xenon Pharmaceuticals from $60.00 to $55.00 and set a "buy" rating for the company in a report on Tuesday, May 13th. Royal Bank Of Canada decreased their target price on Xenon Pharmaceuticals from $57.00 to $55.00 and set an "outperform" rating for the company in a report on Tuesday, August 12th. Evercore ISI began coverage on Xenon Pharmaceuticals in a research note on Wednesday, May 14th. They issued an "outperform" rating and a $55.00 price target on the stock. Finally, Wells Fargo & Company cut their price target on Xenon Pharmaceuticals from $50.00 to $47.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating and eleven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $53.20.

Xenon Pharmaceuticals Stock Performance

Shares of XENE traded up $0.27 during midday trading on Thursday, hitting $38.23. 820,100 shares of the stock were exchanged, compared to its average volume of 1,051,328. Xenon Pharmaceuticals has a 52-week low of $26.74 and a 52-week high of $46.00. The stock has a fifty day simple moving average of $32.59 and a 200 day simple moving average of $34.02. The firm has a market cap of $2.95 billion, a P/E ratio of -10.77 and a beta of 1.16.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($1.03) by ($0.04). During the same period in the prior year, the firm posted ($0.75) earnings per share.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Holocene Advisors LP acquired a new stake in shares of Xenon Pharmaceuticals during the 2nd quarter worth $56,637,000. Geode Capital Management LLC increased its holdings in shares of Xenon Pharmaceuticals by 1,294.2% during the 2nd quarter. Geode Capital Management LLC now owns 970,343 shares of the biopharmaceutical company's stock worth $30,369,000 after buying an additional 900,746 shares during the last quarter. Braidwell LP increased its holdings in shares of Xenon Pharmaceuticals by 33.0% during the 2nd quarter. Braidwell LP now owns 3,605,029 shares of the biopharmaceutical company's stock worth $112,837,000 after buying an additional 895,154 shares during the last quarter. Vestal Point Capital LP increased its holdings in shares of Xenon Pharmaceuticals by 53.8% during the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company's stock worth $62,600,000 after buying an additional 700,000 shares during the last quarter. Finally, Commodore Capital LP increased its holdings in shares of Xenon Pharmaceuticals by 30.1% during the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company's stock worth $94,682,000 after buying an additional 700,000 shares during the last quarter. 95.45% of the stock is currently owned by institutional investors and hedge funds.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.